Open AccessMultiplex RNA‐based detection of clinically relevant MET alterations in advanced non‐small cell lung cancer
Author(s) -
Aguado Cristina,
Teixido Cristina,
Román Ruth,
Reyes Roxana,
GiménezCapitán Ana,
Marin Elba,
Cabrera Carlos,
Viñolas Nuria,
Castillo Sergi,
Muñoz Silvia,
Arcocha Ainara,
LópezVilaró Laura,
Sullivan Ivana,
Aldeguer Erika,
Rodríguez Sonia,
Moya Irene,
Viteri Santiago,
Cardona Andrés Felipe,
Palmero Ramon,
Sainz Cristina,
MesaGuzmán Miguel,
Lozano Maria D.,
AguilarHernández Andrés,
MartínezBueno Alejandro,
GonzálezCao María,
Gonzalvo Elena,
Leenders William P. J.,
Rosell Rafael,
Montuenga Luis M.,
Prat Aleix,
MolinaVila Miguel A.,
Reguart Noemi
Publication year - 2021
Publication title -
molecular oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.332
H-Index - 88
eISSN - 1878-0261
pISSN - 1574-7891
DOI - 10.1002/1878-0261.12861
Subject(s) - lung cancer , fluorescence in situ hybridization , biology , exon , reverse transcriptase , immunohistochemistry , oncology , cancer research , rna , crizotinib , medicine , cancer , microbiology and biotechnology , gene , genetics , malignant pleural effusion , chromosome
We studied MET alterations in 474 advanced non‐small‐cell lung cancer (NSCLC) patients by nCounter, an RNA‐based technique. We identified 3% with MET Δex14 mRNA and 3.5% with very‐high MET mRNA expression, a surrogate of MET amplification. MET alterations identified by nCounter correlated with clinical benefit from MET inhibitors. Quantitative mRNA‐based techniques can improve the selection of patients for MET‐targeted therapies.